A Comprehensive Evaluation of Clinicopathologic Characteristics, Molecular Features and Prognosis in Lung Adenocarcinoma with an Acinar Component

• Published in: Cancers Vol. 17; no. 11; p. 1825
• Main Authors: Abolfathi, Hanie, Kordahi, Manal, Armero, Victoria Saavedra, Gaudreault, Nathalie, Boudreau, Dominique K., Gagné, Andréanne, Orain, Michèle, Fiset, Pierre Oliver, Desmeules, Patrice, Lamaze, Fabien Claude, Bossé, Yohan, Joubert, Philippe
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.05.2025; MDPI
• Subjects: Adenocarcinoma; Analysis; c-Met protein; Cancer; Cancer therapies; Classification; Development and progression; Epidermal growth factor receptors; Kinases; Lung cancer; Medical prognosis; Medical research; Medicine, Experimental; Mutation; Patients; Prognosis; Survival; Tumors; Tyrosine kinase inhibitors; Massachusetts; United States > US; acinar; gene mutations; prognosis; lung adenocarcinoma; histological pattern
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers17111825

Introduction: Lung adenocarcinoma (LUAD) is the leading cause of cancer-related mortality worldwide. Acinar is the most prevalent architectural pattern and is associated with an intermediate prognosis. Several studies have investigated the prognosis of acinar-predominant LUAD patients. Here, we aimed to move beyond the acinar-predominant classification and gain a more comprehensive understanding of how acinar minor components influence prognosis specifically when accompanying other histological patterns in LUAD. Methods: Patients were grouped by the proportion of acinar patterns in their tumors: acinar-predominant (AP), and acinar component (AC; non-acinar predominant LUAD with an acinar component of ≥5%). The clinicopathologic characteristics, recurrence-free survival (RFS), and a panel of well-characterized driver mutations, including KRAS, EGFR, BRAF, MET, and PIK3CA, were investigated in the two groups of patients. Results: Among 1263 LUAD patients, 716 (56.7%) were AP, and 547 (43.3%) were AC. In AP, the frequency of EGFR exon 19 deletions (EGFR-Del 19) was significantly higher than in AC (p = 0.014). AC demonstrated a worse RFS than AP in the unadjusted analysis (log-rank p: 0.006). In stage I, the difference in the RFS of AC in comparison to AP remained significant (p = 0.048). In the multivariable analysis, AC was significantly associated with a worse RFS in comparison to AP (hazard ratio [HR] AC vs. AP: 1.240, 95% CI: 1.103–1.312, p: 0.04), even after adjusting for other histological patterns, the mutational status, and relevant clinicopathological features. The post-recurrence survival was significantly better in patients with an acinar component of ≥5% who received EGFR tyrosine kinase inhibitors (TKIs) compared to those who did not receive TKIs (p = 0.033). Conclusions: While the predominant pattern primarily dictates prognosis in LAUD, the presence of an acinar minor component alongside other high-grade patterns may further worsen outcomes. This underscores the necessity of considering the broader histological landscape rather than focusing solely on predominant patterns, as our findings show that minor acinar components can impact RFS alongside other histological patterns.